Membranoproliferative Glomerulonephritis (MPGN)
4 clinical trials · Condition
◉ Watch Membranoproliferative Glomerulonephritis (MPGN)
| Record | Firm | Date |
|---|---|---|
| Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (NCT05067127) | Apellis Pharmaceuticals, Inc. | 2021-11-12 |
| Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN (NCT04572854) | Apellis Pharmaceuticals, Inc. | 2021-09-07 |
| C3G/Primary IC-MPGN EAP (NCT04729062) | Apellis Pharmaceuticals, Inc. |
Track Membranoproliferative Glomerulonephritis (MPGN) automatically
Every clearance here is in the API, with alerts when new ones post.